Biosimilar Analysis · Medicare Part B

What Medicare pays for every biosimilar

Pick a molecule to compare CMS payment limits against the reference product, with a link to each drug page. Q4 2026 data, refreshed October 6.

  • 71 biosimilars
  • 16 molecules
  • 55 price pairs

Figures are free CMS payment limits. True ASP, WAC & AWP come with a 7-day free trial →

Choose a molecule

Payment limit · Q4 2026

Avastin Ref

J9035 · Reference · since 2005

$75.492 per 10 mg
REF
+3.8% · 2 yrs

Vegzelma

Q5129 · Celltrion USA · entered 2023

$21.139 per 10 mg
−72.0%
−62.8% · 2 yrs

Zirabev

Q5118 · Pfizer · entered 2019

$25.939 per 10 mg
−65.6%
+10.0% · 2 yrs

Mvasi

Q5107 · Amgen · entered 2019

$28.294 per 10 mg
−62.5%
+6.4% · 2 yrs

Alymsys

Q5126 · Amneal Pharmaceuticals · entered 2023

$79.982 per 10 mg
+5.9%
+64.2% · 2 yrs

Jobevne

Q5160 · Biocon Biologics · entered 2026

$82.139 per 10 mg
+8.8%
−0.1% since Q3 '26
Priced per 10 mg · vs Avastin Open full analysis →
▼ 92.0% Ruxience vs Rituxan ▼ 83.6% Trazimera vs Herceptin ▼ 77.8% Wezlana vs Stelara ▼ 74.3% Enoby and Xtrenbo vs Xgeva ▼ 72.2% Fulphila vs Neulasta ▼ 72.0% Vegzelma vs Avastin ▼ 71.8% Steqeyma vs Stelara ▼ 70.8% Riabni vs Rituxan ▼ 69.9% Yesintek vs Stelara ▼ 69.0% Releuko vs Neupogen

Trusted by Leading Healthcare Organizations

Head to Head

Any two products, side by side

Put the reference against a biosimilar — or two biosimilars against each other — and compare price, direction, and market tenure at a glance.

Product A

Reference J9035

Avastin

$75.492

Medicare payment limit per 10 mg · Q4 2026

+3.8% · 2 yrs
Payment-limit trend
+3.8% · 2 yrs
HCPCS code since
2005

Product B

Biosimilar Q5129

Vegzelma

$21.139

Medicare payment limit per 10 mg · Q4 2026

−62.8% · 2 yrs
Manufacturer
Celltrion USA
Payment-limit trend
−62.8% · 2 yrs
HCPCS code since
2023

Vegzelma pays 72.0% less per unit than Avastin.

Beyond the CMS file

22 biosimilars are coded but have no published Medicare rate

These products already carry a HCPCS code, but CMS has published no Q4 2026 payment limit against it. They span 7 molecules, the oldest coded back in 2024, and they are in the market all the same.

Product Code Manufacturer Coded

Adalimumab 6

Aflibercept 5 Eylea pays $722.251 per 1 mg

Denosumab 5 Xgeva pays $29.856 per 1 mg

Ustekinumab 3 Stelara pays $10.249 per 1 mg

Filgrastim 1 Neupogen pays $0.994 per 1 mcg

Infliximab 1 Remicade pays $29.856 per 10 mg

Omalizumab 1 Xolair pays $45.687 per 5 mg

Who it's for

Built for everyone who touches biosimilar analysis

Four questions this page already answers with Q4 2026 CMS data. Each one opens the tool that answers it.

FAQs

Biosimilar Analysis FAQs

How biosimilar pricing analysis works on BuyandBill.com, and where the data comes from.

Still have a question? Contact us
What is biosimilar analysis?

Comparing a biosimilar with its reference product on price and reimbursement. For Medicare Part B drugs, that means putting ASP, WAC, AWP, and the Medicare Payment Limit side by side and watching how the gap between them moves over time.

How is biosimilar data used in practice?

Practices use it to decide which product to buy and bill. Administrators use the trends for budgeting and forecasting. Payers and consultants use them for formulary and policy reviews, and manufacturers watch competitor prices.

What drug information and pricing data is included for this analysis?

Without an account you get the HCPCS code, billing units, NDC packages, and the Medicare Payment Limit, which is the figure every comparison on this page is built from. ASP, WAC, and AWP need a login, as does pricing history back to January 2015. The biosimilar list itself comes straight from CMS files and is free. For the rest of what governs the claim on any one of these codes, including the MUE cap and whether Part B covers it at all, see Medicare Part B reimbursement.

What is the maximum number of drugs I can compare?

The explorer above shows a whole biosimilar family at once, free. Drug Comparative Graphing charts two drugs at a time, and your first five comparisons need no account. Charting up to 15 codes on one graph, the full comparative report, and history back to January 2015 all require a login.

How often is the data updated?

The Medicare Payment Limit shown here updates each quarter, in January, April, July, and October, and the biosimilar list refreshes whenever CMS updates it. Behind a login, ASP follows the same quarterly schedule while WAC and AWP are refreshed every week, straight from drug manufacturers.

What BuyandBill.com Does

Other Capabilities

NDC Lookup

Search any National Drug Code for its package description, pricing, and aligned HCPCS code.

Explore More →

HCPCS Code Lookup

Search any HCPCS code for its descriptor, aligned NDC packages, pricing, and reimbursement.

Explore More →

Drug Price Lookup & Trends

Track ASP, WAC, and AWP across 10+ years of history in tabular and graphical formats.

Explore More →

Drug Comparative Graphing

Compare ASP, WAC, and AWP across drugs and biosimilars in interactive charts.

Explore More →

Drug Market Research

Track pricing, coding events, and reimbursement trends for physician-administered drugs to guide market decisions.

Explore More →

Billing Calculator

Convert package pricing to billing units and estimate reimbursement in seconds.

Explore More →

Make Biosimilar Analysis Faster and Easier

Compare biosimilars instantly with complete visibility into WAC, AWP, ASP, and Medicare payment limits — all in one place.

Start 7-day free trial → Log In